What We Do News Sarepta Eteplirsen (Exondys 51) Managed Access Program Community Update October 17 Sarepta has made some modifications to their managed access program for eteplirsen. If you or your son took part in the eteplirsen clinical trials for studies such as study 28, study 33 or the Promovi study, and would like access to the drug, please contact your neuromuscular doctor who was responsible for your son whilst he was taking part in the study, or your current neuromuscular doctor. They can, at your request start, the application process for you or your son to receive the drug through the managed access program. Sarepta has made some modifications to the program to allow this specific group of patients access to the drug with no cost to the families. Please do not contact Sarepta or Clinigen directly, all communication must go through your doctor. If you have any questions regarding this program please contact our Director of patient engagement and clinical care Naomi Litchfield at [email protected].